Targeting BRAF in cancers - from molecular diagnostics to personalized therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• BRAF alterations are crucial markers in diverse cancers, influencing the MAPK/ERK pathway.
• Specific BRAF mutations, like V600E, are common drivers in melanoma, thyroid, colorectal, and lung cancers.
• BRAF mutations are classified into three types, impacting therapeutic strategies.

Purpose of the Study:

• To review the role of BRAF mutations in cancer.
• To discuss current and emerging therapeutic strategies targeting BRAF alterations.
• To highlight the importance of molecular diagnostics in personalized cancer care.

Main Methods:

• Review of current literature on BRAF mutations, targeted therapies, and diagnostic methods.
• Analysis of BRAF mutation classes and their clinical significance.
• Discussion of resistance mechanisms and novel treatment approaches.

Main Results:

• Targeted therapies, including BRAF and MEK inhibitors, are effective against specific BRAF mutations (e.g., class I V600E).
• Resistance to BRAF inhibitors necessitates the development of next-generation treatments and combination therapies.
• Immunotherapy shows synergistic potential in BRAF-mutated cancers.
• Various molecular diagnostic techniques exist, with Next-Generation Sequencing (NGS) offering comprehensive genomic profiling.

Conclusions:

• Accurate BRAF molecular profiling is essential for guiding personalized cancer treatment.
• Ongoing research focuses on overcoming therapeutic resistance and integrating advanced diagnostics like ctDNA.
• Optimizing combination therapies and understanding resistance mechanisms are key to improving outcomes for BRAF-driven malignancies.